Info: 120 Vegi-Caps (500 mg)
N-Acetyl-L-Carnitine (ALCAR) is an acetylated form of L-carnitine and has the ability to cross the blood-brain barrier, which may supply the body with a more bioavailable form of L-carnitine.
Info: 120 Vegi-Caps (500 mg)
N-Acetyl-L-Carnitine (ALCAR) is an acetylated form of L-carnitine and has the ability to cross the blood-brain barrier, which may supply the body with a more bioavailable form of L-carnitine.
Product Notes:
L-carnitine, an amino acid, aids in the breakdown of long-chain fatty acids and production of cellular energy, but some adults – especially those with a vegetarian or vegan diet – have difficulty maintaining a healthy intake as L-carnitine is primarily found in red meats.
Studies conducted have shown positive results in the improvement of mental function and energy levels in elderly who have taken ALCAR or those taking the supplement while battling conditions such as liver and kidney disease or chronic fatigue. ALCAR may also help with cognitive function in young and middle-aged adults. In addition, since ALCAR is broken down to L-carnitine in the body, it may also aid in weight loss as L-carnitine is needed in order to properly metabolize fats, sugars, and carbohydrates.
Related Product: See AOR L-Carnitine.
Health Canada Natural Product Number: 80039706.
AOR ALCAR Ingredients:
Each capsule contains:
500 mg N-Acetyl-L-Carnitine (HCl)
Non-medicinal ingredients: microcrystalline cellulose, silicon dioxide, hypromellose (capsule).
Vegan. Non-GMO. Gluten-Free. Part of AOR's Premium series, ALCAR does not contain wheat, gluten, corn, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish, shellfish, or any animal byproduct.
Suggested Usage:
Take 2 to 4 capsules daily with food, or as directed by a healthcare practitioner. A minimum of three months may be required before observing an effect.
Warnings:
This product provides 1.59 g of a single amino acid per day. Consult a healthcare practitioner prior to use if you are pregnant or breastfeeding, have liver or kidney disease, have been instructed to follow a low protein diet, if symptoms persist or worsen or for use beyond 6 months. Feelings of overstimulation and/or sleeplessness may occur, in which case discontinue use if symptoms persist or worsen.
Low incidence of seizures has been reported with oral doses in individuals with or without a pre-existing seizure disorder. Mild gastrointestinal symptoms (transient nausea, vomiting, abdominal cramps and diarrhea) have been reported. Body odor, flatulence, increased appetite or rash may occur.
Supporting Science:
Furlong JH. "Acetyl-L-Carnitine: Metabolism and applications in clinical practice." Altern Med Rev 1996.
"Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha -lipoic acid." Proc Natl Acad Sci USA 2002 Feb 19.
Montgomery SA, Thal LJ, Amrein R. "Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease." Int Clin Psychopharmacol. 2003 Mar.